MESO Mesoblast ADRs

Mesoblast Ltd is engaged in the development of biologic products for the broad field of regenerative medicine. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. This is an ADR of a company whose stock trades outside of the U.S. as the symbol AT:MSB.

$6.83  +0.15 (2.17%)
As of 05/13/2021 10:13:17 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Australia
Country of incorporation:  Australia
IPO date:  01/18/2006
Outstanding shares:  129,739,214
Average volume:  353,017
Market cap:   $921,148,419
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    590717104
ISIN:        US5907171046
Sedol:      
Valuation   (See tab for details)
PE ratio:   -8.93
PB ratio:   1.53
PS ratio:   56.00
Return on equity:   -18.91%
Net income %:   -596.48%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy